Investor Presentaiton

SELECT TRIALS - EARLY PHASE DIABETES AND OBESITY (CONT.) Lilly Molecule Study Indication* Title Phase Patients APOC3 siRNA NCT05609825 Hypertriglyce A Study of LY3875383 in Healthy Participants and ridemia Participants With Hypertriglyceridemia 1 120 NRG4 Agonist NCT04840914| HFrEF A Study of LY3461767 in Participants With Chronic Heart Failure With Reduced Ejection Fraction 1 50 PNPLA3 siRNA NCT05395481 Non- Alcoholic Fatty Liver Disease A Single-Ascending and Repeated Dose Study of LY3849891 in Participants With Nonalcoholic Fatty Liver Disease 1 176 * Molecule may have multiple indications ** Trial may have additional primary and other secondary outcomes Not for promotional use 2023 Q2 EARNINGS Primary Outcome** Primary Completion Completion Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration Part A: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Jan 2024 Jan 2024 Mar 2024 Mar 2024 Serious Adverse Event(s) (SAEs) Considered by the Nov 2024 Nov 2024 Investigator to be Related to Study Drug Administration Source: clinicaltrials.gov, July 13, 2023 53 53

View entire presentation